The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease

O’Donnell, Mark E.; Badger, Stephen A.; Sharif, Mohammed A; Young, Ian S.; Lee, Bernard T.; Soong, Chee V.

doi:10.1016/j.jvs.2008.11.098

Cited by 56 publications

(58 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 Although ABI is an effective and practical method for diagnosis of PAD with 95% sensitivity, 5% of false negatives remain. 21 In this study, the discrepancy potentially might be secondary to a high incidence of noncompliant vessel calcification leading to overestimation.…”

Section: Limitationsmentioning

confidence: 99%

Cilostazol Reduces Angiographic Restenosis After Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol Study

et al. 2013

View full text Add to dashboard Cite

Background-It remains unclear whether cilostazol, which has been shown to improve the clinical outcomes of endovascular therapy for femoropopliteal lesions, also reduces angiographic restenosis. Methods and Results-The Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) study investigated whether cilostazol reduces the 12-month angiographic restenosis rate after percutaneous transluminal angioplasty with provisional nitinol stenting for femoropopliteal lesions. Two hundred patients with femoropopliteal lesions treated from March 2009 to April 2011 at 13 cardiovascular centers were randomly assigned 1:1 to receive oral aspirin with or without cilostazol. The primary end point was 12-month angiographic restenosis rate. Secondary end points were the restenosis rate on duplex ultrasound, the rate of major adverse cardiac events, and target lesion event-free survival. Researchers evaluated all follow-up data and assessed the end points in a blinded fashion. The mean lesion length and reference vessel diameter at the treated segment were 128±86 mm and 5.4±1.4 mm, respectively. The frequency of stent used was similar between groups (88% versus 90% in the cilostazol and noncilostazol group, respectively, P=0.82). During the 12-month follow-up period, 11 patients died and 152 patients (80%) had evaluable angiographic data at 12 months. The angiographic restenosis rate at 12 months was 20% (15/75) in the cilostazol group versus 49% (38/77) in the noncilostazol group (P=0.0001) by intention-to-treat analysis. The cilostazol group also had a significantly higher event-free survival at 12 months (83% versus 71%, P=0.02), although cardiovascular event rates were similar in both groups. Conclusions-Cilostazol reduced angiographic restenosis after percutaneous transluminal angioplasty with provisional nitinol stenting for femoropopliteal lesions. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00912756; and URL: https://www. umin.ac.jp. Unique identifier: UMIN000002091.

show abstract

Section: Limitationsmentioning

confidence: 99%

Cilostazol Reduces Angiographic Restenosis After Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol Study

et al. 2013

View full text Add to dashboard Cite

show abstract

“…After first dosing on Day 8, blood samples were collected at 0 (predose), 1,2,3,4,6,8,10,12,13,14,15,16,18,20,22,24,36,48, and 72 hours for PK. In the case of PD, blood samples were collected at 0 hour (baseline) on Day 1 and 0 (predose), 3,6,8,10,12,15,18,20,22,24,36, 48 and 72 hours after first dosing on Day 8.…”

Section: Study Design and Datamentioning

confidence: 99%

“…[1][2][3] It is also used for the treatment of intracranial atherosclerosis and to prevent cardioembolic stroke in patients undergoing antiplatelet therapy. [4] Cilostazol increases cAMP by inhibiting phosphodiesterase. Accordingly, it increases the active form of protein kinase A (PKA) and finally inhibits platelet aggregation.…”

Section: Introductionmentioning

confidence: 99%

Population pharmacodynamics of cilostazol in healthy Korean subjects

Jung

Chae

Park

2018

Transl Clin Pharmacol

View full text Add to dashboard Cite

“…The favorable clinical outcome of the cilostazol cohort is in addition to the revascularization effect and in line with the results of the conservative treatment studies in which cilostazol significantly improved walking distance compared with placebo. 16 …”

Section: 11mentioning

confidence: 99%

Cilostazol

Zeller

Trenk

2013

Circulation

View full text Add to dashboard Cite

The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease

Abstract: Cilostazol is a well-tolerated, safe, and efficacious treatment for PAD patients. It not only improves patients' symptomatology and quality of life but also appears to have beneficial effects on arterial compliance, possibly through its lipid-lowering property.

Cited by 56 publications

References 35 publications

Cilostazol Reduces Angiographic Restenosis After Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol Study

Cilostazol Reduces Angiographic Restenosis After Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol Study

Population pharmacodynamics of cilostazol in healthy Korean subjects

Cilostazol

Contact Info

Product

Resources

About